Botulinum toxin a has antinociceptive effects in treating interstitial cystitis

Botulinum a Toxin Intravesical Injections in the Treatment of Painful Bladder Syndrome: A Pilot Study

“…Zermann et al showed reduced frequency and increased bladder capacity in 4 of 7 patients with refractory urgency-frequency syndrome who received intravesical Botox targeting the trigone and bladder base [15]. A recent multicenter case series examined the effect of intravesical Botox or Dysport in 13 patients with refractory interstitial cystitis [16]. Overall, 9 of 13 patients (69%) reported a subjective improvement that lasted a mean of 3.72 mo (range, 1-8 mo).…”

“…The sensory efferent actions include the release of transmitters such as adenosine triphosphate (ATP), substance P, and calcitonin gene-related peptide (CGRP) that can act on nearby tissues and on afferent nerve terminals in an autocrine fashion to increase afferent nerve activity [17]. The production and release of these neurotransmitters increase during conditions of inflammation and pain [7,16]. Moreover, many C fibers in the bladder mucosa contain neuropeptides, such as substance P, neurokinin A, and CGRP, which on release, can modulate the micturition reflex and might cause detrusor overactivity [18].…”

Antinociceptive effect of botulinum toxin type A on experimental abdominal pain

“…It was found that local BTX-A injections efficiently decrease pain in patients suffering from bladder pain syndrome/ interstitial cystitis, prostatitis and pelvic-floor muscle disorder (Abbott et al, 2006., Chung et al, 2012, El-Khawand et al, 2013, Gottsch et al, 2011, Kuo, 2013, Pinto et al, 2013, Smith et al, 2004, Zermann et al, 2000. In addition, there are isolated case reports on the beneficial effect of BTX-A on non-cardiac chest pain (Maradey-Romero and Fass, 2014) and perineal pain (Lim et al, 2010).…”

Botulinumtoxin in der Urologie

“…Infolge der Freisetzung der ersten beiden kommt es zur Entladung weiterer entzündungsfördernder Substanzen, z.B. die von Bradykinin (BK), Prostaglandinen (PGs), Histaminen (HA), Serotonin (5-HT) und anderer (Aoki, 2005 (Chuang et al, 2004;Giannantoni et al, 2006a;Rapp et al, 2006;Smith et al, 2004).…”

“…Eine Abnahme (Comperat et al, 2006) oder keine Zunahme der Fibrosierung (Apostolidis et al, 2008b; wurde nach einer einzelnen bzw. nach wiederholten Injektionen in die Blase bei NDO oder IDO beobachtet (LoE 2b entsprechend den Vorgaben der European Association of Urology (Apostolidis et al, 2008a) (Giannantoni et al, 2006a;Giannantoni et al, 2008;Kuo, 2005b;Liu and Kuo, 2007;Smith et al, 2004 (Giannantoni et al, 2006a;Giannantoni et al, 2008;Liu and Kuo, 2007;Smith et al, 2004). Eine Studie berichtete über eine lediglich 20%ige…”